Continuum Advisory’s Charles River Laboratories CRL Stock Holding History

Continuum Advisory’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.4K	Buy	+134	New	+$23.9K	﹤0.01%	927
2025 Q2	–	Sell	-9	Closed	-$1.35K	–	641
2025 Q1	$1.35K	Sell	9 -9	-50%	-$1.51K	﹤0.01%	1452
2024 Q4	$3.32K	Hold	18	–	–	﹤0.01%	1251
2024 Q3	$3.54K	Buy	18 +2	+13%	+$416	﹤0.01%	1254
2024 Q2	$3.31K	Hold	16	–	–	﹤0.01%	1180
2024 Q1	$3.68K	Buy	+16	New	+$3.82K	﹤0.01%	1137
2023 Q3	–	Sell	-997	Closed	-$210K	–	455
2023 Q2	$210K	Buy	+997	New	+$198K	0.03%	425
2022 Q3	–	Sell	-1,130	Closed	-$242K	–	409
2022 Q2	$242K	Sell	1,130 -296	-21%	-$72.3K	0.04%	363
2022 Q1	$344K	Buy	1,426 +781	+121%	+$241K	0.07%	292
2021 Q4	$243K	Sell	645 -97	-13%	-$37.7K	0.05%	265
2021 Q3	$306K	Hold	742	–	–	0.08%	223
2021 Q2	$274K	Buy	+742	New	+$248K	0.09%	222

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Continuum Advisory's CRL Position: Q2 2026 in Review

Continuum Advisory opened a new position in Charles River Laboratories (CRL) in Q2 2026: 134 shares worth $30.4K. The stake represents ﹤0.01% of the portfolio and ranks #927 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in CRL as recently as Q1 2025.

Continuum Advisory first reported a position in CRL in Q2 2021 and has held it in 12 quarters since. The position peaked at $344K in Q1 2022. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Continuum Advisory held 134 shares of Charles River Laboratories worth $30.4K as of Q2 2026.
Charles River Laboratories was a new Continuum Advisory position in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #927 holding.
Continuum Advisory first reported a position in Charles River Laboratories in Q2 2021 and has held it in 12 quarters since.
Continuum Advisory's Charles River Laboratories position peaked at $344K in Q1 2022.
569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.